Clinical end pharmacoeconomic aspects of neoadjuvant therapy of breast cancer
Achievement of complete Pathomorphologic Response (pCR) after neoadjuvant therapy of breast cancer significantly improves long-term treatment outcome. Correlation between pCR and long-term treatment outcome is strongest in HER2-positive breast cancer; this data clearly supports use of double HER2-bl...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2018-07-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/2545 |
| _version_ | 1797841326143700992 |
|---|---|
| author | V. A. Kostorov T. Yu. Semiglazova A. V. Pavlysh |
| author_facet | V. A. Kostorov T. Yu. Semiglazova A. V. Pavlysh |
| author_sort | V. A. Kostorov |
| collection | DOAJ |
| description | Achievement of complete Pathomorphologic Response (pCR) after neoadjuvant therapy of breast cancer significantly improves long-term treatment outcome. Correlation between pCR and long-term treatment outcome is strongest in HER2-positive breast cancer; this data clearly supports use of double HER2-blockade in neoadjuvant breast cancer therapy. However, the high cost of targeted drugs requires pharmacoecomomic assessments for choosing of the most optimal treatment course. |
| first_indexed | 2024-04-09T16:29:11Z |
| format | Article |
| id | doaj.art-f4fcdb5613d048fbabcf309211b0eb10 |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:29:11Z |
| publishDate | 2018-07-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-f4fcdb5613d048fbabcf309211b0eb102023-04-23T06:57:11ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902018-07-0101014014510.21518/2079-701X-2018-10-140-1452506Clinical end pharmacoeconomic aspects of neoadjuvant therapy of breast cancerV. A. Kostorov0T. Yu. Semiglazova1A. V. Pavlysh2State Budget Healthcare Institution «Leningrad regional oncology dispensary»Federal State Budget Healthcare Institution «National Medical Research Oncology Center named after N.N. Petrov»Federal State Budget Healthcare Institution «National Medical Research Oncology Center named after N.N. Petrov»Achievement of complete Pathomorphologic Response (pCR) after neoadjuvant therapy of breast cancer significantly improves long-term treatment outcome. Correlation between pCR and long-term treatment outcome is strongest in HER2-positive breast cancer; this data clearly supports use of double HER2-blockade in neoadjuvant breast cancer therapy. However, the high cost of targeted drugs requires pharmacoecomomic assessments for choosing of the most optimal treatment course.https://www.med-sovet.pro/jour/article/view/2545her-positive breast cancerneoadjuvant therapydouble anti-her2-blockadepertuzumabtrastuzumab |
| spellingShingle | V. A. Kostorov T. Yu. Semiglazova A. V. Pavlysh Clinical end pharmacoeconomic aspects of neoadjuvant therapy of breast cancer Медицинский совет her-positive breast cancer neoadjuvant therapy double anti-her2-blockade pertuzumab trastuzumab |
| title | Clinical end pharmacoeconomic aspects of neoadjuvant therapy of breast cancer |
| title_full | Clinical end pharmacoeconomic aspects of neoadjuvant therapy of breast cancer |
| title_fullStr | Clinical end pharmacoeconomic aspects of neoadjuvant therapy of breast cancer |
| title_full_unstemmed | Clinical end pharmacoeconomic aspects of neoadjuvant therapy of breast cancer |
| title_short | Clinical end pharmacoeconomic aspects of neoadjuvant therapy of breast cancer |
| title_sort | clinical end pharmacoeconomic aspects of neoadjuvant therapy of breast cancer |
| topic | her-positive breast cancer neoadjuvant therapy double anti-her2-blockade pertuzumab trastuzumab |
| url | https://www.med-sovet.pro/jour/article/view/2545 |
| work_keys_str_mv | AT vakostorov clinicalendpharmacoeconomicaspectsofneoadjuvanttherapyofbreastcancer AT tyusemiglazova clinicalendpharmacoeconomicaspectsofneoadjuvanttherapyofbreastcancer AT avpavlysh clinicalendpharmacoeconomicaspectsofneoadjuvanttherapyofbreastcancer |